Dashboard
1
Poor Management Efficiency with a low ROCE of 5.32%
- The company has been able to generate a Return on Capital Employed (avg) of 5.32% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -9.90% and Operating profit at -168.34% over the last 5 years
3
Negative results in Mar 25
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.93%
0%
-12.93%
6 Months
-23.5%
0%
-23.5%
1 Year
77.69%
0%
77.69%
2 Years
51.89%
0%
51.89%
3 Years
35.03%
0%
35.03%
4 Years
48.44%
0%
48.44%
5 Years
45.28%
0%
45.28%
Qianjiang Yongan Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-9.90%
EBIT Growth (5y)
-168.34%
EBIT to Interest (avg)
14.14
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.46
Tax Ratio
18.84%
Dividend Payout Ratio
47.46%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.32%
ROE (avg)
4.31%
Valuation key factors
Factor
Value
P/E Ratio
227
Industry P/E
Price to Book Value
2.15
EV to EBIT
-141.47
EV to EBITDA
36.44
EV to Capital Employed
3.09
EV to Sales
4.32
PEG Ratio
1.41
Dividend Yield
0.70%
ROCE (Latest)
-2.19%
ROE (Latest)
0.94%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
194.00
168.20
15.34%
Operating Profit (PBDIT) excl Other Income
33.90
15.90
113.21%
Interest
0.30
0.20
50.00%
Exceptional Items
4.40
-2.40
283.33%
Consolidate Net Profit
15.30
-6.70
328.36%
Operating Profit Margin (Excl OI)
27.80%
-74.80%
10.26%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 15.34% vs -22.95% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 328.36% vs -844.44% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
829.40
962.80
-13.86%
Operating Profit (PBDIT) excl Other Income
151.80
159.50
-4.83%
Interest
0.80
0.60
33.33%
Exceptional Items
-22.80
-108.20
78.93%
Consolidate Net Profit
59.70
-28.40
310.21%
Operating Profit Margin (Excl OI)
46.90%
25.20%
2.17%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -13.86% vs -33.55% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 310.21% vs -121.43% in Dec 2023
About Qianjiang Yongan Pharmaceutical Co., Ltd. 
Qianjiang Yongan Pharmaceutical Co., Ltd.
Specialty Chemicals
No Details Available.
Company Coordinates 
No Company Details Available






